thyroid-associated orbitopathy and idiopathic orbital inflammatory syndrome
Conditions
Interventions
Group A:rituximab 10mg
Group B:rituximab 20mg
Group C:rituximab 10mg
Sponsors
Department of Ophthalmology, Tangdu Hospital, Fourth Military Medical University
Eligibility
Sex/Gender
All
Age
5 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Patients clearly diagnosed as IOID or TAO. 2. The age ranges from 6 to 75 years old, regardless of gender. 3. Agree to join the group and sign a written informed consent form. 4. Exclude patients from the criteria. 5. Those who have good compliance and agree to take drugs and accept evaluation in accordance with the requirements of the research program.
Exclusion criteria
Exclusion criteria: 1. Complicated with other orbital diseases. 2. Patients with hematological diseases who are using hormones or similar experimental drugs. 3. Patients who have participated in clinical trials of other drugs or at the same time within 3 months before treatment. 4. Women during pregnancy, lactation, or women of childbearing age who are willing to become pregnant. 5. People who are allergic to rituximab or allergic to rituximab. 6. Alcoholism, drug addicts or other uncontrollable neuropsychiatric disorders are not suitable for drug testing. 7. The researchers believe that it is not appropriate for patients to participate in other conditions of this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CAS; | — |
Countries
China
Contacts
Public ContactYang-Jun Li
Tangdu Hospital, the Fourth Military Medical University
Outcome results
None listed